Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel S Key

Showing results (231-240 of 255) with videos related to

Pageof 26
Sort By:
Frontiers in Medicine|May 28, 2024
Angiopoietin2 is associated with coagulation activation and tissue factor expression in extracellular vesicles in COVID-19Mayck Silva Barbosa, Franciele de Lima, Carla Roberta Peachazepi Moraes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2019
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateNigel S Key, Alok A Khorana, Nicole M Kuderer, et al.
American Journal of Hematology|April 8, 2017
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopeniaDavid J Kuter, Barbara A Konkle, Taye H Hamza, et al.
The Journal of Trauma and Acute Care Surgery|May 27, 2021
Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus ConferencePhilip C Spinella, Nahed El Kassar, Andrew P Cap, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 18, 2015
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis NetworkElena Holm, Thomas C Abshire, Joel Bowen, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline updateGary H Lyman, Alok A Khorana, Nicole M Kuderer, et al.
Research and Practice in Thrombosis and Haemostasis|May 1, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial resultsAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014Gary H Lyman, Kari Bohlke, Alok A Khorana, et al.
Pageof 26

Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
Frontiers in Medicine|May 28, 2024
Angiopoietin2 is associated with coagulation activation and tissue factor expression in extracellular vesicles in COVID-19Mayck Silva Barbosa, Franciele de Lima, Carla Roberta Peachazepi Moraes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2019
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateNigel S Key, Alok A Khorana, Nicole M Kuderer, et al.
American Journal of Hematology|April 8, 2017
Clinical outcomes in a cohort of patients with heparin-induced thrombocytopeniaDavid J Kuter, Barbara A Konkle, Taye H Hamza, et al.
The Journal of Trauma and Acute Care Surgery|May 27, 2021
Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus ConferencePhilip C Spinella, Nahed El Kassar, Andrew P Cap, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 18, 2015
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis NetworkElena Holm, Thomas C Abshire, Joel Bowen, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline updateGary H Lyman, Alok A Khorana, Nicole M Kuderer, et al.
Research and Practice in Thrombosis and Haemostasis|May 1, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial resultsAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014Gary H Lyman, Kari Bohlke, Alok A Khorana, et al.
Pageof 26